Welcome to the Starpharma Investor CentreStarpharma Holdings Limited is an Australian stock exchange listed biotechnology company with products based on its dendrimer technology platform. |
 |
|
|
Latest News & Announcements
Medicxi and Starpharma create Petalion Therapeutics to develop novel dendrimer-based treatments (ASX Announcement)
Apr 8th, 2024
Medicxi to invest up to USD $25M into newly established entity, Petalion Therapeutics, led by highly experienced pharmaceutical executive Dr Mehdi Shahidi
Read More
Half Yearly Report and Accounts (ASX Announcement)
Feb 28th, 2024
Starpharma (ASX: SPL, OTCQX: SPHRY) today releases its Interim Report and Half-Year Financial Results for the period ended 31 December 2023 (H1 FY24).
Read More
Reports & Presentations
Click here for financial reports archive
Investor Webinar - Starpharma and Medicxi Partnership: Petalion Therapeutics (9 April 2024)
Apr 10th, 2024
Starpharma hosted an investor webinar on Tuesday, 9 April 2024. The session focused on the ASX Announcement lodged on 8 April 2024, 'Starpharma and Medicxi Partnership Petalion Therapeutics', about the strategic partnership with Medicxi and the formation of a new company called Petalion Therapeutics.
Read More
Breaking new ground via an oncology treatment tech venture
Apr 9th, 2024
Cheryl Maley, CEO of Starpharma (SPL), provides insight into the partnreship with Medicxi, materialising in Petalion Therapeutics in the UK.
Read More